EUVIMEDEUVIMED entdecken
Kohortenstudie

Oncological Outcomes After Cytoreductive Surgery and HIPEC for Colorectal and Appendiceal Peritoneal Metastases: A Retrospective Cohort Study

S Hügli, A Anranter, S Suter, D Eshmuminov, P Kron, J Oberholzer, P Limani

British Journal of Surgery · 03.06.2026 · 113 (Supplement_5)

DOI: 10.1093/bjs/znag055.083 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Surgery, online erschienen am 03.06.2026. Verfasst von S Hügli und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is an established treatment for peritoneal metastases from colorectal cancer (PM-CRC) and appendiceal tumors, with favorable outcomes reported in pseudomyxoma peritonei. However, oncological outcomes vary by tumor entity and disease burden.

Aims

This study aimed to evaluate oncological outcomes and identify prognostic factors for cancer-specific survival (CSS) and disease-free survival (DFS) following CRS/HIPEC for PM-CRC and appendiceal peritoneal metastases.

Methods

This retrospective single-center cohort study included 135 patients treated with CRS/HIPEC for PM-CRC or metastatic appendiceal tumors, including low- and high-grade appendiceal mucinous neoplasms (LAMN, HAMN) and appendiceal carcinoma (AC), between 2014 and 2024. Primary endpoints were CSS and DFS; secondary endpoints included postoperative morbidity and major complications. Survival was analyzed using the Kaplan-Meier method with log-rank testing for comparison between tumor entities. Prognostic factors were assessed using univariate and multivariate Cox proportional hazards models.

Results

The cohort comprised 37 LAMN, 4 HAMN, 28 AC and 67 PM-CRC patients. Complete cytoreduction (CC-0/1) was achieved in 93% of cases. Median peritoneal cancer index was 11. The median overall survival was not reached for LAMN and HAMN, was 57.9 months for AC, and 31.4 months for PM-CRC, with significant differences between tumor entities (p<0.001). Positive lymph node status was associated with reduced CSS (HR 4.61, 95% CI 2.31-9.22; p<0.001) and DFS (HR 3.84, 95% CI 2.29-6.46; p<0.001). Small bowel resection was associated with reduced CSS (HR 1.79, 95% CI 1.02-3.09; p=0.04) and DFS (HR 1.75, 95% CI 1.11-2.77; p=0.02). Incomplete cytoreduction was associated with shorter CSS (HR 2.43, 95% CI 1.14-5.15; p=0.02).

Conclusion

CRS/HIPEC provides favorable long-term outcomes in selected patients with peritoneal metastases, particularly those with appendiceal tumors. Tumor entity, lymph node status, completeness of cytoreduction, and small bowel resection significantly influence oncological outcomes, emphasizing the importance of careful patient selection.

Zitieren

APA

Hügli, S., Anranter, A., Suter, S., Eshmuminov, D., Kron, P., Oberholzer, J., & Limani, P. (2026). Oncological Outcomes After Cytoreductive Surgery and HIPEC for Colorectal and Appendiceal Peritoneal Metastases: A Retrospective Cohort Study. British Journal of Surgery, 113(Supplement_5). https://doi.org/10.1093/bjs/znag055.083

Vancouver

Hügli S, Anranter A, Suter S, Eshmuminov D, Kron P, Oberholzer J, et al. Oncological Outcomes After Cytoreductive Surgery and HIPEC for Colorectal and Appendiceal Peritoneal Metastases: A Retrospective Cohort Study. British Journal of Surgery. 2026;113(Supplement_5). doi:10.1093/bjs/znag055.083

BibTeX
@article{Hgli2026,
  author = {Hügli, S and Anranter, A and Suter, S and Eshmuminov, D and Kron, P and Oberholzer, J and Limani, P},
  title = {Oncological Outcomes After Cytoreductive Surgery and HIPEC for Colorectal and Appendiceal Peritoneal Metastases: A Retrospective Cohort Study},
  journal = {British Journal of Surgery},
  year = {2026},
  volume = {113},
  number = {Supplement_5},
  doi = {10.1093/bjs/znag055.083}
}
Kostenlos starten →